Investment Thesis
Immix Biopharma is an early-stage pharmaceutical company with minimal revenue ($20M) and severe operating losses (-$10.8M), producing negative margins of -54% and unsustainable negative free cash flow of -$9.8M annually. While the fortress balance sheet with $79.3M in cash and zero debt provides 8+ years of operational runway, current fundamentals reveal a company burning cash with no evidence of profitability trajectory without significant revenue expansion or cost restructuring.
Strengths
- Fortress balance sheet with $79.3M cash and zero debt eliminating financial distress risk
- Exceptional liquidity position (8.76x current ratio) providing substantial operational runway and flexibility
- Some revenue generation ($20M) indicates product commercialization has initiated beyond pure R&D stage
Risks
- Severe operating unprofitability with -54% operating margin indicating fundamental business model unsustainability at current scale
- Continuous negative free cash flow (-$9.8M annually) despite small revenue base suggests structural cost issues requiring resolution
- Pharmaceutical sector inherent risks including regulatory approval uncertainty, clinical trial failures, patent challenges, and competitive landscape threats
Key Metrics to Watch
- Revenue growth rate and gross margin expansion demonstrating commercialization traction and unit economics improvement
- Operating cash burn trajectory and cash runway depletion timeline necessitating future capital raises
- Pipeline advancement stage, regulatory milestones, and approval probability of key development candidates driving long-term value
Financial Metrics
Revenue
20.0M
Net Income
-10.1M
EPS (Diluted)
$-0.18
Free Cash Flow
-9.9M
Total Assets
95.8M
Cash
79.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-54.0%
Net Margin
-50.4%
ROE
-12.0%
ROA
-10.5%
FCF Margin
-49.3%
Balance Sheet & Liquidity
Current Ratio
8.76x
Quick Ratio
8.76x
Debt/Equity
0.00x
Debt/Assets
12.0%
Interest Coverage
-21,738.14x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:23:14.505820 |
Data as of: 2026-03-31 |
Powered by Claude AI